Guarantee safety: Pre-clinical testing reveals AAV antibodies in patient sera, enabling secure and efficient gene transfer
Save time: Skip the lengthy process of identifying AAV-positive reference serum with our ready-to-use solution
Meet FDA standards: Pre-testing patient sera is crucial for adhering to FDA guidelines
Ensure consistency: These antibodies, closely resembling human samples, offer lot-to-lot consistency and comparability
Description
These human chimeric AAV antibodies serve as a dependable assay control for detecting AAV antibodies in human sera, derived from PROGEN's unique collection of neutralizing anti-AAV mouse monoclonal antibodies. They share the same variable region, but feature a human Fc region, enabling recognition by anti-human secondary antibodies and ensuring comparability with human serum antibodies.
